Pharmacokinetics and Safety of Single and Multiple Oral Doses of Meloxicam in Adult Horses

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

BACKGROUND: Safety of meloxicam, a potent NSAID with selective COX-2 inhibition, has not been evaluated in horses.OBJECTIVES: To evaluate pharmacokinetics and safety of single and repeated oral doses of meloxicam in adult horses.ANIMALS: Forty-nine healthy, university-owned adult lightbreed horses.METHODS: Study conducted in 2 parts. Part I addressed pharmacokinetics of single oral dose meloxicam (0.6 mg/kg) in 16 horses. Part II, 33 horses were randomly assigned to 5 treatment groups to assess prolonged administration (0.6 mg/kg PO q24h for 6 weeks, n = 7) or higher doses (1.8 mg/kg, n = 7, or 3.0 mg/kg PO q24h, n = 7) of meloxicam for 2 weeks, compared with control horses (placebo, n = 7, or phenylbutazone, 4.4 mg/kg q12h on day 1, 2.2 mg/kg q12h for 4 days, then 2.2 mg/kg q24h for 9 days, n = 5).RESULTS: Maximum plasma concentration following a single oral dose of meloxicam was 915.1 ± 116.9 ng/mL and elimination half-life 10.2 ± 3.0 hours. Meloxicam (0.6 mg/kg, q24h, PO for 6 weeks) yielded plasma concentrations between 100 and 1000 ng/mL and was well tolerated by healthy adult horses. Administration of 3-5 times the recommended dose of meloxicam was associated with decreased total serum protein and albumin concentrations, gastrointestinal damage, renal damage, or bone marrow dyscrasia. PBZ administration was associated with the development right dorsal colitis, gastric ulceration, and protein losing enteropathy in 2 horses.CONCLUSIONS AND CLINICAL IMPORTANCE: Administration meloxicam at 0.6 mg/kg q24h was well tolerated for 6 weeks, without drug accumulation in plasma. Higher doses were associated with dose-dependent adverse effects typical of class of drugs.
Original languageEnglish
Pages (from-to)1192-1201
Number of pages10
JournalJournal of Veterinary Internal Medicine
Volume26
Issue number5
DOIs
Publication statusPublished - Sep 2012

Fingerprint

meloxicam
pharmacokinetics
Horses
mouth
Pharmacokinetics
Safety
horses
dosage
Protein-Losing Enteropathies
phenylbutazone
Phenylbutazone
drugs
nonsteroidal anti-inflammatory agents
colitis
Non-Steroidal Anti-Inflammatory Agents
serum albumin
prostaglandin synthase
Colitis
digestive system diseases
Serum Albumin

Cite this

@article{0c99014ed814412eb62b22f3efb23730,
title = "Pharmacokinetics and Safety of Single and Multiple Oral Doses of Meloxicam in Adult Horses",
abstract = "BACKGROUND: Safety of meloxicam, a potent NSAID with selective COX-2 inhibition, has not been evaluated in horses.OBJECTIVES: To evaluate pharmacokinetics and safety of single and repeated oral doses of meloxicam in adult horses.ANIMALS: Forty-nine healthy, university-owned adult lightbreed horses.METHODS: Study conducted in 2 parts. Part I addressed pharmacokinetics of single oral dose meloxicam (0.6 mg/kg) in 16 horses. Part II, 33 horses were randomly assigned to 5 treatment groups to assess prolonged administration (0.6 mg/kg PO q24h for 6 weeks, n = 7) or higher doses (1.8 mg/kg, n = 7, or 3.0 mg/kg PO q24h, n = 7) of meloxicam for 2 weeks, compared with control horses (placebo, n = 7, or phenylbutazone, 4.4 mg/kg q12h on day 1, 2.2 mg/kg q12h for 4 days, then 2.2 mg/kg q24h for 9 days, n = 5).RESULTS: Maximum plasma concentration following a single oral dose of meloxicam was 915.1 ± 116.9 ng/mL and elimination half-life 10.2 ± 3.0 hours. Meloxicam (0.6 mg/kg, q24h, PO for 6 weeks) yielded plasma concentrations between 100 and 1000 ng/mL and was well tolerated by healthy adult horses. Administration of 3-5 times the recommended dose of meloxicam was associated with decreased total serum protein and albumin concentrations, gastrointestinal damage, renal damage, or bone marrow dyscrasia. PBZ administration was associated with the development right dorsal colitis, gastric ulceration, and protein losing enteropathy in 2 horses.CONCLUSIONS AND CLINICAL IMPORTANCE: Administration meloxicam at 0.6 mg/kg q24h was well tolerated for 6 weeks, without drug accumulation in plasma. Higher doses were associated with dose-dependent adverse effects typical of class of drugs.",
author = "Glenys Noble and Scott Edwards and Jan Lievaart and J. Pippia and R. Boston and Sharanne Raidal",
note = "Imported on 12 Apr 2017 - DigiTool details were: month (773h) = September, 2012; Journal title (773t) = Journal of Veterinary Internal Medicine. ISSNs: 1939-1676;",
year = "2012",
month = "9",
doi = "10.1111/j.1939-1676.2012.00976.x",
language = "English",
volume = "26",
pages = "1192--1201",
journal = "Journal of Veterinary Internal Medicine",
issn = "0891-6640",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Pharmacokinetics and Safety of Single and Multiple Oral Doses of Meloxicam in Adult Horses

AU - Noble, Glenys

AU - Edwards, Scott

AU - Lievaart, Jan

AU - Pippia, J.

AU - Boston, R.

AU - Raidal, Sharanne

N1 - Imported on 12 Apr 2017 - DigiTool details were: month (773h) = September, 2012; Journal title (773t) = Journal of Veterinary Internal Medicine. ISSNs: 1939-1676;

PY - 2012/9

Y1 - 2012/9

N2 - BACKGROUND: Safety of meloxicam, a potent NSAID with selective COX-2 inhibition, has not been evaluated in horses.OBJECTIVES: To evaluate pharmacokinetics and safety of single and repeated oral doses of meloxicam in adult horses.ANIMALS: Forty-nine healthy, university-owned adult lightbreed horses.METHODS: Study conducted in 2 parts. Part I addressed pharmacokinetics of single oral dose meloxicam (0.6 mg/kg) in 16 horses. Part II, 33 horses were randomly assigned to 5 treatment groups to assess prolonged administration (0.6 mg/kg PO q24h for 6 weeks, n = 7) or higher doses (1.8 mg/kg, n = 7, or 3.0 mg/kg PO q24h, n = 7) of meloxicam for 2 weeks, compared with control horses (placebo, n = 7, or phenylbutazone, 4.4 mg/kg q12h on day 1, 2.2 mg/kg q12h for 4 days, then 2.2 mg/kg q24h for 9 days, n = 5).RESULTS: Maximum plasma concentration following a single oral dose of meloxicam was 915.1 ± 116.9 ng/mL and elimination half-life 10.2 ± 3.0 hours. Meloxicam (0.6 mg/kg, q24h, PO for 6 weeks) yielded plasma concentrations between 100 and 1000 ng/mL and was well tolerated by healthy adult horses. Administration of 3-5 times the recommended dose of meloxicam was associated with decreased total serum protein and albumin concentrations, gastrointestinal damage, renal damage, or bone marrow dyscrasia. PBZ administration was associated with the development right dorsal colitis, gastric ulceration, and protein losing enteropathy in 2 horses.CONCLUSIONS AND CLINICAL IMPORTANCE: Administration meloxicam at 0.6 mg/kg q24h was well tolerated for 6 weeks, without drug accumulation in plasma. Higher doses were associated with dose-dependent adverse effects typical of class of drugs.

AB - BACKGROUND: Safety of meloxicam, a potent NSAID with selective COX-2 inhibition, has not been evaluated in horses.OBJECTIVES: To evaluate pharmacokinetics and safety of single and repeated oral doses of meloxicam in adult horses.ANIMALS: Forty-nine healthy, university-owned adult lightbreed horses.METHODS: Study conducted in 2 parts. Part I addressed pharmacokinetics of single oral dose meloxicam (0.6 mg/kg) in 16 horses. Part II, 33 horses were randomly assigned to 5 treatment groups to assess prolonged administration (0.6 mg/kg PO q24h for 6 weeks, n = 7) or higher doses (1.8 mg/kg, n = 7, or 3.0 mg/kg PO q24h, n = 7) of meloxicam for 2 weeks, compared with control horses (placebo, n = 7, or phenylbutazone, 4.4 mg/kg q12h on day 1, 2.2 mg/kg q12h for 4 days, then 2.2 mg/kg q24h for 9 days, n = 5).RESULTS: Maximum plasma concentration following a single oral dose of meloxicam was 915.1 ± 116.9 ng/mL and elimination half-life 10.2 ± 3.0 hours. Meloxicam (0.6 mg/kg, q24h, PO for 6 weeks) yielded plasma concentrations between 100 and 1000 ng/mL and was well tolerated by healthy adult horses. Administration of 3-5 times the recommended dose of meloxicam was associated with decreased total serum protein and albumin concentrations, gastrointestinal damage, renal damage, or bone marrow dyscrasia. PBZ administration was associated with the development right dorsal colitis, gastric ulceration, and protein losing enteropathy in 2 horses.CONCLUSIONS AND CLINICAL IMPORTANCE: Administration meloxicam at 0.6 mg/kg q24h was well tolerated for 6 weeks, without drug accumulation in plasma. Higher doses were associated with dose-dependent adverse effects typical of class of drugs.

U2 - 10.1111/j.1939-1676.2012.00976.x

DO - 10.1111/j.1939-1676.2012.00976.x

M3 - Article

VL - 26

SP - 1192

EP - 1201

JO - Journal of Veterinary Internal Medicine

JF - Journal of Veterinary Internal Medicine

SN - 0891-6640

IS - 5

ER -